Seres Therapeutics stands out as a pioneering force in the biotech industry, being the first to gain FDA approval for an orally administered microbiota-based therapeutic, VOWST™, to prevent recurrence of C. difficile infection. The company's culture is deeply rooted in scientific exploration and collaboration, as evidenced by their partnership with Nestlé Health Science and ongoing research in areas such as gastrointestinal infections and ulcerative colitis. Their commitment to transforming patient lives through advanced microbiome therapeutics positions them as a leader in their field, offering employees the opportunity to contribute to groundbreaking work in a supportive, forward-thinking environment.